Articles from Corcym

Corcym, a global medical device company dedicated to cardiac surgery, today announced that positive mid-term data from a sub-analysis of its Perceval Plus sutureless aortic heart valve as part of its MANTRA clinical trial was featured in an oral presentation today at the annual meeting of the European Association for Cardio-Thoracic Surgery (EACTS). The study is the longest follow-up available for Perceval Plus and the FREE tissue treatment from an international multicenter study, and demonstrated excellent durability, safety and quality of life improvements.

Corcym, a global medical device company dedicated to cardiac surgery, today announced the first-in-human implant of Memo 4D Curve™, a semi-rigid open-configuration annuloplasty ring for mitral valve repair. The procedure was performed by Michael Ibrahim, MD, PhD at UVA Health University Medical Center.

Corcym, a global medical device company dedicated to cardiac surgery, today announced the first-in-human implantation of TriMemo®, a semi-rigid annuloplasty ring dedicated to tricuspid valve repair. The procedure was performed at Cleveland Clinic by A. Marc Gillinov, MD, Chairman of the Department of Thoracic and Cardiovascular Surgery and Judith Dion Pyle Chair in Heart Valve Research.

CORCYM, the medical device company dedicated to providing patients and cardiac surgeons with the best solutions to fight structural heart disease, announces today the first Perceval implant in China, after the recent approval from the NMPA - National Medical Products Administration.

CORCYM, the new, independent, medical device company dedicated to providing patients and cardiac surgeons with the best solutions to fight structural heart disease, announces today the enrollment of the first patient in the MANTRA study. MANTRA (Mitral, Aortic aNd Tricuspid post-maRket Study in a reAl-world setting) is a prospective, multi-arm, multi-center, global, post-market clinical follow-up study that monitors the safety and performance of the complete CORCYM portfolio in a real-world setting.

CORCYM the new, independent, medical device company dedicated to providing patients and heart surgeons with the best solutions to fight structural heart disease, announces today the launch of operations globally. Born from the acquisition of the LivaNova PLC (LivaNova) heart valve business by Gyrus Capital (Gyrus), an investment firm dedicated to investments in the healthcare and sustainability sectors, CORCYM enters the market with a comprehensive portfolio of products to fit the needs of heart surgeons and patients worldwide.